Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 25249523.
- Also identified by DOI 10.1093/cid/ciu742.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Twenty-four solid-organ-transplant recipients with chronic hepatitis E virus (HEV) infections were given ribavirin therapy for 3 months. All the patients with protracted fecal HEV shedding during treatment suffered a relapse. Monitoring HEV fecal excretion could be used to determine the optimal duration of ribavirin therapy.
Medical subject headings
- Antiviral Agents
- Feces
- Hepatitis E
- Hepatitis E virus
- Ribavirin
- Virus Shedding